摘要
目的评价国产仿制品注射用美罗培南(倍能)对细菌性感染的临床有效性及安全性。方法采用随机开放、平行对照试验设计,以进口注射用美罗培南(美平)作对照药物。结果倍能与美平的临床有效率分别为81.60%和82.39%,细菌清除率分别为88.64%和91.10%,不良反应发生率为5.52%和5.11%,两组差异无统计学意义(P>0.05)。结论注射用美罗培南(倍能)治疗细菌性感染疗效肯定且安全性较高。
Objective To evaluate the efficacy and safety of domestic meropenem （Beineng） injection in treatment of severe bactenal infection. Methods A randomized controlled clinical trial was conducted, while the imported meropenem （Mepem） was used as the control. Results The overall efficacy rates of Beineng and Mepem were 81.60% and 82.39%, respectively. The bacterial clearance rates were 88.64% and 91.10%, respectively. The incidence rates of adverse reaction were 5.52% and 5.11%, respectively. There was no significant difference between the two groups for the above results. Conclusions Domestic meropenem （Beineng） injection is an antibacterial agent for bacterial infection with high efficacy and safety.
出处
《中华实验和临床感染病杂志（电子版）》
CAS
2012年第4期69-72,共4页
Chinese Journal of Experimental and Clinical Infectious Diseases(Electronic Edition)
关键词
美罗培南
细菌感染
治疗结果
Meropenem （Beineng）
Bacterial infections
Treatment outcome
